Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
spirationinc.com

See what CB Insights has to offer

Founded Year

1999

Stage

Acquired | Acquired

Total Raised

$108.45M

About Spiration

Spiration was founded to develop treatments for chronic obstructive pulmonary disease.

Spiration Headquarter Location

6675 185th Avenue NE

Redmond, Washington, 98052,

United States

425-497-1700

Latest Spiration News

Anthem Blue Cross And Blue Shield Adds Coverage For Severe Emphysema Treatment

Sep 30, 2021

Anthem Blue Cross And Blue Shield Adds Coverage For Severe Emphysema Treatment Minimally Invasive Spiration® Valve System Now Available to Blue Cross Blue Shield Members in 14 States Author: Sep 30, 2021 10:17 AM EDT CENTER VALLEY, Pa., Sept. 30, 2021 /PRNewswire/ -- Olympus today announced that Anthem Blue Cross Blue Shield, the second largest commercial health plan in the country, has updated their coverage policy to include the Spiration Valve System for patients suffering from severe emphysema, a form of COPD (Chronic Obstructive Pulmonary Disease). This follows positive coverage decisions by other BCBS plans, extending coverage for endobronchial valve therapy in the U.S. The Spiration Valve System provides a minimally invasive treatment that has been shown to improve lung function and reduce breathlessness for eligible patients who are suffering from the debilitating symptoms of severe emphysema. i Anthem is the largest independent licensee of the Blue Cross and Blue Shield Association, covering more than 33 million lives through their commercial and governmental plan types. ii The new commercial policy covers beneficiaries across 14 states: California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, New Hampshire, Nevada, New York, Ohio, Virginia and Wisconsin. iii This positive coverage decision adds to a growing list of insurance companies that now cover endobronchial valve treatment, including Blue Cross and Blue Shield Association licensees Highmark and Health Care Service Corporation, Blue Cross Blue Shield North Carolina, Massachusetts, Michigan and North Dakota, Aetna, and Humana. "This decision by Anthem will provide expanded access to a critical new therapy for patients suffering the breathlessness that comes with severe emphysema," said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. "Olympus is very proud of its role in developing minimally invasive treatment options that provide an alternative to open surgery, which can further compromise patients who are already vulnerable with a chronic condition like emphysema." "Clinical trials have proven that bronchoscopic lung volume reduction (BLVR) with endobronchial valves demonstrates statistically significant and clinically meaningful improvements in lung function, reduction in shortness of breath and improvement in quality of life compared to standard of care medical management," said Dr. Grant Pierson, Pulmonologist with Freeman Health System in Joplin, MO. iv,v For information about the Spiration Valve System, visit these dedicated websites: For patients and their families:  https://svs.olympusamerica.com/patients-and-family Full prescriptive information:  https://svs.olympusamerica.com/prescriptive-information About Olympus Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries. Olympus' Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of EndoTherapy instruments. For more information, visit www.medical.olympusamerica.com . i Prescriptive Information. svs.olympusamerica.com. https://svs.olympusamerica.com/prescriptive-information . Published March 2019. Accessed September 14, 2021.  ii Data Sourced by Policy Reporter, a TrialCard Company. Accessed August 31, 2021. iii Stats & Facts. Antheminc.com. https://www.antheminc.com/NewsMedia/FrequentlyRequestedMaterials/StatsFacts/index.htm. Published 2020. Accessed September 22, 2021. iv Criner GJ, Delage A, Voelker K, et al. "Improving lung function in severe heterogenous emphysema with the Spiration® Valve System (EMPROVE): a multicenter, open-label, randomized, controlled trial." American Journal of Respiratory and Critical Care Medicine. 2019;200(11):1354-1362, 2019 v Wang G, Li S, Wang C, et. al. The REACH study, a randomized controlled trial assessing the safety and effectiveness of the Spiration Valve System endobronchial therapy for severe emphysema: 12 month follow-up results. European Respiratory Journal. 2017; 50(61); DOI: 10.1183/1393003.congress-2017.OA1465 View original content to download multimedia: https://www.prnewswire.com/news-releases/anthem-blue-cross-and-blue-shield-adds-coverage-for-severe-emphysema-treatment-301388970.html SOURCE Olympus Medical Systems Group By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Spiration

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Spiration is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,383 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Spiration Patents

Spiration has filed 131 patents.

The 3 most popular patent topics include:

  • Medical equipment
  • Endoscopy
  • Surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/8/2018

11/9/2021

Medical equipment, Experimental cancer drugs, Lymphatics of the head and neck, Monoclonal antibodies, Implants (medicine)

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/8/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/9/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Medical equipment, Experimental cancer drugs, Lymphatics of the head and neck, Monoclonal antibodies, Implants (medicine)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.